Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Vusolimogene oderparepvec by Replimune for Basal Cell Carcinoma (Basal Cell Epithelioma): Likelihood of Approval
Vusolimogene oderparepvec is under clinical development by Replimune and currently in Phase II for Basal Cell Carcinoma (Basal Cell Epithelioma)....
Vusolimogene oderparepvec by Replimune for Metastatic Melanoma: Likelihood of Approval
Vusolimogene oderparepvec is under clinical development by Replimune and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase...
Vusolimogene oderparepvec by Replimune for Melanoma: Likelihood of Approval
Vusolimogene oderparepvec is under clinical development by Replimune and currently in Pre-Registration for Melanoma. According to GlobalData, Pre-Registration drugs for...
Vusolimogene oderparepvec by Replimune for Merkel Cell Carcinoma: Likelihood of Approval
Vusolimogene oderparepvec is under clinical development by Replimune and currently in Phase II for Merkel Cell Carcinoma. According to GlobalData,...
Vusolimogene oderparepvec by Replimune for Angiosarcoma: Likelihood of Approval
Vusolimogene oderparepvec is under clinical development by Replimune and currently in Phase II for Angiosarcoma. According to GlobalData, Phase II...
Vusolimogene oderparepvec by Replimune for Nonmelanomatous Skin Cancer: Likelihood of Approval
Vusolimogene oderparepvec is under clinical development by Replimune and currently in Phase II for Nonmelanomatous Skin Cancer. According to GlobalData,...
Vusolimogene oderparepvec by Replimune for Esophageal Cancer: Likelihood of Approval
Vusolimogene oderparepvec is under clinical development by Replimune and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase...
Vusolimogene oderparepvec by Replimune for Non-Small Cell Lung Cancer: Likelihood of Approval
Vusolimogene oderparepvec is under clinical development by Replimune and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Vusolimogene oderparepvec by Replimune for Metastatic Breast Cancer: Likelihood of Approval
Vusolimogene oderparepvec is under clinical development by Replimune and currently in Phase II for Metastatic Breast Cancer. According to GlobalData,...
Vusolimogene oderparepvec by Replimune for Bladder Cancer: Likelihood of Approval
Vusolimogene oderparepvec is under clinical development by Replimune and currently in Phase II for Bladder Cancer. According to GlobalData, Phase...
Vusolimogene oderparepvec by Replimune for Colorectal Cancer: Likelihood of Approval
Vusolimogene oderparepvec is under clinical development by Replimune and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase...
Vusolimogene oderparepvec by Replimune for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Vusolimogene oderparepvec is under clinical development by Replimune and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...
Vusolimogene oderparepvec by Replimune for Melanoma: Likelihood of Approval
Vusolimogene oderparepvec is under clinical development by Replimune and currently in Pre-Registration for Melanoma. According to GlobalData, Pre-Registration drugs for...
Vusolimogene oderparepvec by Replimune for Merkel Cell Carcinoma: Likelihood of Approval
Vusolimogene oderparepvec is under clinical development by Replimune and currently in Phase II for Merkel Cell Carcinoma. According to GlobalData,...